In non-small cell lung cancer (NSCLC), targetable driver alterations include ALK*, RET**, and ROS1*** fusions. DNA-based and RNA-based next-generation sequencing each have advantages and drawbacks for detecting gene fusions. In this webinar, expert speakers will present their perspectives on fusion detection in NSCLC.

Attendees Will Learn:
- Summary of currently approved therapies for fusions in NSCLC.
- Methods and recommendations for fusion detection with comprehensive genomic profiling.
- The pros and cons of DNA and RNA sequencing for fusion detection.
- About fusion detection in the context of a hypothetical patient case.

Speakers:

Mark Socinski, MD
Executive Director (Thoracic Cancer), Medical Oncologist
AdventHealth Cancer Institute
Orlando, FL

Holli Dilks, PhD
Senior Director, Global Head of Field Medical
Foundation Medicine
Boston, MA

* Anaplastic lymphoma kinase (ALK)
** rearranged during transfection (RET)
*** ROS proto-oncogene 1, receptor tyrosine kinase (ROS1)